Program
Z 338
Also written as “Z-338”, “YM443” and “Acotiamide hydrochloride hydrate”.
Its studies are mostly in Dyspepsia, led by 3 companies.
Drug pageZ 338: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zeria Pharmaceuticalits history only | 70 open or running | phase 3since Sep 25, 2008 | Feb 28, 2006 | none ahead |
| Astellas Pharmaits history only | 40 open or running | phase 3since Sep 30, 2008 | Jan 26, 2005 | none ahead |
| Getz Pharma | 11 open or running | phase 3since Sep 12, 2025 | Sep 12, 2025 | Dec 30, 2026phase 3 · NCT07174297 |
Also a collaborator on its studies: Astellas Pharma US.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Getz Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 12, 2025First study: phase 3 study in Postprandial Distress SyndromeFirst studyNCT07174297 · 152 planned
Ahead
- Dec 30, 2026Primary completion: phase 3 study in Postprandial Distress SyndromeNCT07174297
TargetBeta
“Acetylcholinesterase inhibitor”ChEMBL 37, by rule
Other programs on ACHE
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Donepezilrule | Eisai | phase 4 | 83 |
| huperzine Arule | wanbangde-pharmaceutical-group-co-ltd | phase 4 | 7 |
| benzgalantamine gluconaterule | alpha-cognition-inc | phase 4 | 1 |
Studies
The one study Getz Pharma leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07174297Postprandial Distress Syndrome | 3 | Not yet recruiting | Dec 30, 2026 | 152 |
How it is read
Names in the registry
- “Z-338”, 7 entries
- “YM443”, 3 entries
- “Acotiamide hydrochloride hydrate”, 1 entry
- “Acotiamide”, 1 entry
Conditions, from the studies’ own filings
- Dyspepsia, 10 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.